Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 16. Отображено 16.
19-09-2013 дата публикации

Control of Blood Vessel Physiology To Treat Skin Disorders

Номер: US20130245538A1
Автор: Carter Stephen G., Donabedian David H., Masiz John J., Patel Kanu, Stephens Laura, Zhu Zhen
Принадлежит: BIOCHEMICS, INC.

In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by inducing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing. 1. A method for treating an affected skin region of a patient having a skin disorder , the method comprising:a) applying a vasodilation composition to an affected skin region of a patient, said affected skin region exhibiting a skin disorder characterized by at least one abnormal blood vessel, wherein said blood vessel comprises a tissue architecture, and where said application is for a time sufficient to induce vasodilation of said at least one abnormal blood vessel in said affected skin region; andb) non-invasively disrupting the tissue architecture of said at least one abnormal blood vessel.2. The method of claim 1 , wherein said skin disorder is rosacea.3. The method of claim 1 , wherein said skin disorder is telangiectasia.4. The method of claim 1 , wherein said skin disorder comprises at least one vascular lesion.5. The method of claim 1 , wherein said skin disorder is selected from the group consisting of spider veins claim 1 , varicose veins claim 1 , actinically damaged skin claim 1 , venous hypertension claim 1 , Poikiloderma vasculare atrophicans claim 1 , vascular malformations claim 1 , and hemangioma.6. The method of claim 1 , wherein said vasodilation composition comprises arginine.7. The method of claim 6 , wherein said vasodilation composition further comprises tolazoline.8. The method of claim 1 , wherein said vasodilation composition comprises methyl nicotinate. ...

Подробнее
Номер записи: 1
28-07-2016 дата публикации

Methods and Compositions for Tattoo Removal

Номер: US20160213586A1
Автор: Carter Stephen G., Donabedian David H., Kozwich Diane L., Masiz John J., Patel Kanu, Stephens Laura, Zhu Zhen
Принадлежит:

Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle. 1. A method of removing a tattoo from a region of skin , the method comprisingtreating the region with a cell disruptor so as to cause cells of the skin to rupture; andadministering to the same region a tattoo removal composition comprising a vasodilator, at least one osmotic modifying agent and at least one chelating agent, so as to cause enlargement of blood vessels in the region, so that action of the composition and the cell disruptor causes removal of the tattoo.2. (canceled)3. (canceled)4. (canceled)5. The method of claim 1 , wherein administering the composition includes applying the composition topically to the region.6. The method of claim 1 , wherein administering the composition includes applying the composition via a transdermal patch.7. The method of claim 1 , wherein administering the composition includes injecting the composition into the region of skin with a suitable medical device.8. The method of claim 7 , wherein injecting the composition includes using any one of a hypodermic needle claim 7 , a syringe claim 7 , and a needleless injection device.9. The method of claim 1 , wherein administering the composition includes delivering the composition by one or more of a topical formulation claim 1 , a patch-like device claim 1 , an iontophoresis device claim 1 , a sonophoresis device claim 1 , and an injection.10. The method of claim 1 , wherein administering the composition includes covering the region with a non-breathable occlusive barrier that dries on the skin.11. The method of claim 1 , wherein administering the composition includes covering the region with a physical non-breathable occlusive ...

Подробнее
Номер записи: 2
25-10-2018 дата публикации

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Номер: US20180303876A1
Автор: Anthony Stewart CAMPBELL, David H. Donabedian
Принадлежит: Axial Biotherapeutics Inc

The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.

Подробнее
Номер записи: 3
26-11-2020 дата публикации

GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS

Номер: US20200368276A1
Автор: Campbell Anthony Stewart, Donabedian David H.
Принадлежит:

The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders. 1. (canceled)2. A method of treating a subject having a behavioral symptom of a neurological disorder associated with autism spectrum disorder , comprising:administering to the subject a therapeutically effective amount of an activated carbon sequestrant composition which binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract;wherein the at least one intestinal metabolite is 4-ethylphenol and the behavioral symptom is clinical irritability;wherein the sequestrant composition comprises a multiplicity of biocompatible particles which are non-absorbable by the digestive tract of the subject;wherein the therapeutically effective amount is 35 mg to 35 g per day;and wherein the therapeutically effective amount alleviates the clinical irritability. This application is a continuation of U.S. application Ser. No. 16/827,629, filed Mar. 23, 2020, which is a continuation of U.S. application Ser. No. 15/994,571, filed May 31, 2018, which is a continuation of International Application No. PCT/US2018/025607, filed Mar. 31, 2018 which claims the benefit of U.S. Provisional Application Ser. No. 62/480,039, filed Mar. 31, 2017, each of which is hereby expressly incorporated by reference in its entirety.The present disclosure relates to methods of treating, inhibiting, or ameliorating a behavioral symptoms of a neurological disorder, such as autism, and associated pathologies including intestinal ...

Подробнее
Номер записи: 4
17-12-2020 дата публикации

GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS

Номер: US20200390809A1
Автор: Campbell Anthony Stewart, Donabedian David H.
Принадлежит: Axial Biotherapeutics, Inc.

The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders. 114.-. (canceled)15. A sequestrant composition for use in the treatment of a subject having a behavioral symptom of a neurological disorder associated with intestinal hyperpermeability or intestinal dysbiosis , comprising:a multiplicity of biocompatible particles and/or polymers which are non-absorbable by the digestive tract of the subject,wherein the sequestrant composition binds to at least a fraction of at least one intestinal metabolite present in the digestive tract of the subject to form a sequestrant-metabolite complex, such that the sequestrant-metabolite complex is eliminated from the digestive tract, andwherein the intestinal metabolite is associated with the development or presence of the behavioral symptom.16. The sequestrant composition of wherein:the sequestrant composition comprises activated carbon particles, a clay, an apatite or hydroxyapatite, a bentonite, a kaolin, a pectin, a cellulose polymer, a cellulose acetate polymer, a cellulose acetate propionate, an ion exchange resin, a cholestyramine polymer, a tetraethylenepentamine polymer, a phenolic resin, a boronic acid-presenting polymer, a catechin-presenting polymer, or a zeolite.17. The sequestrant composition of comprising:an AB-2004 preparation comprising spherical activated carbon particles having:{'sup': 2', '2, '(a) a minimum average specific surface area determined by the Brunauer-Emmett-Teller (BET) method of at least 500 m/g and a maximum average specific surface area determined by the Brunauer-Emmett-Teller (BET) method less than 4000 m/g; and/or'}(b) a minimum average particle ...

Подробнее
Номер записи: 5
08-03-2016 дата публикации

Methods and compositions for tattoo removal

Номер: US9278233B2
Автор: David H. Donabedian, Diane L. Kozwich, John J. Masiz, Kanu Patel, Laura Stephens, Stephen G. Carter, Zhen Zhu
Принадлежит: Biochemics Inc

Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.

Подробнее
Номер записи: 6
07-07-1998 дата публикации

Cationic therapeutic systems

Номер: JPH10182498A
Автор: David H Donabedian, Dona J Ing, Lawrence Marlin, イング、ドナ、ジェイ, ドナベディアン、デイビッド、エイチ, マーリン、ローレンス
Принадлежит: Union Carbide Chemicals and Plastics Technology LLC

(57)【要約】 【課題】 カチオン治療システムを提供する。 【解決手段】 本発明はカチオン治療剤を粘膜表面へデ リバリーし、それらを通用させるためのカチオン重合体 を、随意的にはアニオン重合体と共に包含するデリバリ ーシステムに関する。特に、これらのデリバリーシステ ムは持続デリバリーシステムによる眼圧及び緑内障の治 療に好適である。

Подробнее
Номер записи: 7
17-12-2009 дата публикации

Control of blood vessel physiology to treat skin disorders

Номер: CA2727710A1
Автор: David H. Donabedian, John J. Masiz, Kanu Patel, Laura Stephens, Stephen G. Carter, Zhen Zhu
Принадлежит: Biochemics Inc

In a method for treating an affected skin region of a patient having a skin disorder, a vasodilation composition is applied to an affected skin region of a patient, the affected skin region exhibiting a skin disorder characterized by at least one ab-normal blood vessel, and the affected skin region is then treated so as to non-invasively disrupt tissue architecture, e.g., by induc-ing ischemia, of the at least one abnormal blood vessel. A vasoconstriction composition can then be applied to the skin region to cause vasoconstriction of the at least one blood vessel in order to promote healing.

Подробнее
Номер записи: 8
20-11-2001 дата публикации

Endovascular apparatus

Номер: US6319276B1
Автор: Darlene A. Thometz, David H. Donabedian, Fertac Bilge, Paul J. Buscemi, Thomas J. Holman
Принадлежит: Scimed Life Systems Inc

Percutaneous treatment of aortic aneurysms and like vascular anomalies by an apparatus and method wherein the apparatus is delivered via catheter and comprises a sleeve with at least one peripheral conduit which is caused to assume an expanded, rigid configuration by the introduction of a chemical or mechanical hardening means, whereby the sleeve is caused to assume an open cylindrical configuration for fluid flow therethrough.

Подробнее
Номер записи: 9
21-08-1997 дата публикации

Endovascular apparatus

Номер: CA2246355A1
Автор: Darlene A. Thometz, David H. Donabedian, Fertac Bilge, Paul J. Buscemi, Thomas J. Holman
Принадлежит: Darlene A. Thometz, David H. Donabedian, Fertac Bilge, Paul J. Buscemi, Scimed Life Systems, Inc., Thomas J. Holman

Percutaneous treatment of aortic aneurysms and like vascular anomalies by an apparatus and method wherein the apparatus is delivered via catheter and comprises a sleeve with at least one peripheral conduit which is caused to assume an expanded, rigid configuration by the introduction of a chemical or mechanical hardening means, whereby the sleeve is caused to assume an open cylindrical configuration for fluid flow therethrough.

Подробнее
Номер записи: 10
14-10-2021 дата публикации

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Номер: AU2021206871B2
Автор: Anthony Stewart CAMPBELL, David H. Donabedian
Принадлежит: Axial Therapeutics Inc

GUT-SELECTIVE SEQUESTERING AGENTS FOR THE TREATMENT AND PREVENTION OF AUTISM AND RELATED DISORDERS ABSTRACT 5 The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders. 10 3/7 Marble Burying EPM Open/Closed 0 -8 0 00 0 Fig. 3

Подробнее
Номер записи: 11
21-08-1997 дата публикации

Endovascular apparatus

Номер: CA2420638A1
Автор: Darlene A. Thometz, David H. Donabedian, Fertac Bilge, Paul J. Buscemi, Thomas J. Holman
Принадлежит: Darlene A. Thometz, David H. Donabedian, Fertac Bilge, Paul J. Buscemi, Scimed Life Systems, Inc., Thomas J. Holman

Percutaneous treatment of aortic aneurysms and like vascular anomalies by an apparatus and method wherein the apparatus is delivered via catheter and comprises s sleeve with at least one peripheral conduit which is caused to assume are expanded, rigid configuration by the introduction of a chemical or mechanical hardening means, whereby the sleeve is caused to assume an open cylindrical configuration for fluid flow therethrough.

Подробнее
Номер записи: 12
08-04-2008 дата публикации

Endovascular apparatus

Номер: CA2420638C
Автор: Darlene A. Thometz, David H. Donabedian, Fertac Bilge, Paul J. Buscemi, Thomas J. Holman
Принадлежит: Scimed Life Systems Inc

Percutaneous treatment of aortic aneurysms and like vascular anomalies by an apparatus and method wherein the apparatus is delivered via catheter and comprises s sleeve with at least one peripheral conduit which is caused to assume are expanded, rigid configuration by the introduction of a chemical or mechanical hardening means, whereby the sleeve is caused to assume an open cylindrical configuration for fluid flow therethrough.

Подробнее
Номер записи: 13
18-06-2019 дата публикации

Methods and compositions for tattoo removal

Номер: US10322077B2
Автор: David H. Donabedian, Diane L. Kozwich, John J. Masiz, Kanu Patel, Laura Stephens, Stephen G. Carter, Zhen Zhu
Принадлежит: Biochemics Inc

Methods and formulations for removing a tattoo by using a cell disrupter in combination with a vasodilator, and optionally one or more of an osmotic modifying agent, a chelation agent, and an occlusive modifying agent. Embodiments optionally further include using one or more of an antibiotic, anesthetic, penetration enhancer, excipient, carrier and vehicle.

Подробнее
Номер записи: 14
18-04-2023 дата публикации

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Номер: CA3095724C
Автор: Anthony Stewart CAMPBELL, David H. Donabedian
Принадлежит: Axial Therapeutics Inc

The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.

Подробнее
Номер записи: 15
16-11-2023 дата публикации

Gut-selective sequestering agents for the treatment and prevention of autism and related disorders

Номер: US20230364135A1
Автор: Anthony Stewart CAMPBELL, David H. Donabedian
Принадлежит: Axial Biotherapeutics Inc

The present disclosure describes methods and compositions for the treatment of neurological disorders and related symptoms by the in vivo sequestration and excretion of microbial metabolites. These metabolites are related to neurological disorders such as autism and Parkinson's disease, as well as intestinal hyperpermeability (leaky gut) and gastrointestinal comorbidities associated with such disorders.

Подробнее
Номер записи: 16